Thursday, 16 July 2020

Fibrocystic Breasts Diagnostics and Treatment Market Overview By Trends, Industry Top Manufactures, Size, Industry Growth Analysis & Forecast Till 2023

Global Fibrocystic Breasts Diagnostics and Treatment Market: Type (Diagnosis- Mammogram and Breast Biopsy, Treatment- Medications, Fine-Needle Aspiration, Surgical Excision, Oral Contraceptives), End-Users (Hospitals and Others)–Global Forecast Till 2023
More than half of women experience fibrocystic breast changes at some point in their lives. According to the American Cancer Society's evaluations, there are chances of around 266,120 new cases of breast cancer may be identified only in 2018 and about 40,920 women may die due to breast cancer.
The fibrocystic breast disease, also known as fibrocystic change or fibrocystic breasts, is a non-cancerous condition in which the breasts feel lumpy. The breast lumps are due to fibrocystic changes. These lumps are formed due to the collection of fibrous tissue at an area of the breast. The ligaments and scar tissues are made up of fibrous tissue. the changes in breast tissue due to the fluctuating hormone levels made by the ovaries results in the occurrence of fibrocystic breasts. The changes seem to be troublesome and result in breast swelling and painful breast lumps. It mainly affects women between their 30s and 50s and lingers through their perimenopause and menopause. Presence of fibrocystic breast disease increases the risk of breast cancer.
The global fibrocystic breasts diagnostics and treatment market is expected to register a significant growth during the forecast period (2018–2023).
Increase in incidences of breast cancer; especially among women above the age of 35 during menopause (are more susceptible to breast cancer), and growth in awareness regarding breast cancer screening programs drive the market growth. Additionally, the emergence of technologically advanced and minimally invasive breast biopsy devices is expected to provide lucrative opportunities in the untapped market.  However, unspecified regulatory issues, infection risks connected with breast biopsy procedures, and ambiguous reimbursement policies are the factors limiting the market growth. Moreover, restrains for the market includes the high cost of the surgical procedure and the risks involved in the procedures are likely to affect the global fibrocystic breasts diagnostics and treatment negatively. 
Key Players
Some of the key players in the global fibrocystic breast diagnostics and treatment market are Argon Medical Devices, Boston Scientific, CareFusion Corporation (Acquired by Becton, Dickinson and Company), C. R. Bard, Inc, Cook Medical, Devicor Medical Products Inc., Gallini Medical Devices, Hologic, Inc., INRAD, Inc., Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd, Bayer AG, Allergan plc.
Regional Analysis
In the fibrocystic breast diagnostics and treatment market, North America is anticipated to account for largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into cancer diagnostic. Whereas the market share in Asia-Pacific region is also projected to experience growth in the near future due to access to optimal treatment facilities and growing demand for advanced technology, better adoption rate, increasing government initiatives and rising healthcare expenditure.
The European market is expected to hold the second largest market share. The market growth in this region can be attributed to increasing amount of alcohol consumption by women, changes in estrogen levels due to increase in intake of birth control pills and increasing use of hormone replacement therapy (HRT) are boosting the European market.
The market in the Middle East & Africa is expected to account for the smallest share of the global fibrocystic breast diagnostics and treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Segmentation
The global fibrocystic breasts diagnostics and treatment market has been segmented into type and end users.
On the basis of type, the market has been classified as diagnosis and treatment. The diagnosis is segmented into mammogram and breast biopsy. The treatment is segmented into medications, fine-needle aspiration, surgical excision, oral contraceptives. The medications are further segmented into acetaminophen, nonsteroidal anti-inflammatory drugs.
On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics, rehab centers, research institutes, and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
The European fibrocystic breasts diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The fibrocystic breasts diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The fibrocystic breasts diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.
Posted by at No comments:

World Distraction Osteogenesis Devices Market Top Key Players Shares, Revenue, Analysis And Forecasts To 2023

Market Scenario:
Global Distraction Osteogenesis Devices Market Insights asserts, the market is expected to grow significantly over the forecast period. Distraction osteogenesis is the biological process of the new bone formation between bone segments which are gradually separated by incremental traction.  
Numerous factors such as advancements in distractor devices such as miniaturized internal and external devices, easily placeable and easy handling are expected to drive the growth of the market. For instance, In May 2018, DePuy Synthes, a part of the Johnson & Johnson Medical Devices Companies, announced an exclusive agreement in the US between DePuy Synthes Sales, Inc. and Prosidyan to promote the Fibergraft family of products, a line of synthetic bone graft materials which are ultra-porous, designed for ease of use, and have been engineered for ideal resorption in clinical use during spine fusion surgery. By adding Fibergraft to its offerings, DePuy Synthes will further enhance the company’s portfolio of biomaterials and distractors.
Moreover, various risks such as failure to follow the distraction protocol and damages to nerves hamper the market growth during the assessment period.
Key players
Johnson & Johnson Services, Inc., Zimmer Biomet Holdings, Inc., Stryker Corporation, KLS Martin Group, Osteomed, Acumed LLC, Jeil Medical Corporation, Ningbo Cibei Medical Treatment Appliance Co., Ltd. Ortho Max Manufacturing Company Pvt. Ltd., Ortho Care and Titamed are some of the key players in the global distraction osteogenesis devices market.
Segmentation
The Global Distraction Osteogenesis Devices Market has been segmented into device type, age, application, and end-user.
The market, based on device type, has been segmented into mandibular distraction devices, palatal distraction devices, alveolar distraction devices, craniofacial distraction devices, Lefort distraction devices, small bone distraction devices, and others. The market, based on craniofacial distraction devices, has been further segmented into external and internal distractors. The market, based on external distractors is further classified into unidirectional distractors, bidirectional distractors, and multiplanar distractors whereas the market, based on, internal distractors can be classified into tooth-borne distractors, bone-borne distractors, and hybrid distractors. The market, by age, has been segmented into pediatrics and adults. The market, by application, has been segmented into dentistry, podiatry, orthopedics, and others. The market, by end-user, has been segmented into hospitals, orthopedic clinics, and others.
Regional Market Summary
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Distraction Osteogenesis Devices Market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European distraction osteogenesis devices market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The Distraction Osteogenesis Devices Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The distraction osteogenesis devices market in the Middle East & Africa has been segmented into the Middle East and Africa.
Geographically, North America is expected to dominate the global distraction osteogenesis devices market owing to increasing number of procedures for treating facial abnormalities in the US. Also, most of the key players have their research and development teams working in this field in the US which in turn increases the awareness among the people about the technique in this region.
The European market is expected to be the second-largest due to increase in initiatives taken by public and private organizations in this field.
Posted by at No comments:

Wednesday, 15 July 2020

Healthcare Personal Protection Equipment Market 2019 – Leading Manufactures, Regions, Drivers, Analysis And Forecasts Till 2025

Market Forecast
Global Healthcare Personal Protection Equipment Market is expected to cross USD 10.116 Billion by 2027 at a CAGR of 9.17%.  
Market Synopsis
Personal Protective Equipment (PPEs) are protective gear designed to safeguard the health of workers by minimizing the exposure to a biological agent. It is one of the necessary tools in preventing transmission of infectious diseases not only in treatment centers but also in various activities, e.g. cleaning, waste management and safe burials, and community care related to the outbreak. Components of PPE are goggles, face-shield, mask, gloves, coverall/gowns (with or without aprons), head cover, shoe cover, and others.
Healthcare Personal Protection Equipment Market Influencer
PPE helps healthcare workers to fight against novel coronavirus (COVID-19). The World Health Organization (WHO) has recommended the governments across the world to increase the production of masks, gloves, respirators, and coveralls/gowns. It also recommended that PPE manufacturers must increase their production by 40% and prioritizing their orders to the countries with a high demand-supply gap.
Market Drivers
  • As of the 3rd week of April, coronavirus (COVID-19) pandemic crossed 2 million cases globally. The increasing demand for hand protection, respiratory protection, and protective clothing in the healthcare industry to ensure the people’s safety during the ongoing COVID-19 pandemic is expected to boost the demand for Personal Protective Equipment (PPE).
  • Rapid technological advancements in the field of surgery such as High-Reliability Organizing (HRO), technical advancements, and standardizing procedures are expected to have a positive impact on the hospital sector, thereby impacting the demand for personal protective equipment positively.
  • Increasing government initiatives to facilitate the import of personal protective equipment is expected to drive the market growth. For instance, in March 2020, in response to the COVID-19 outbreak, the Food and Drug Administration (FDA) initiated numerous steps to improve US stocks of personal protective equipment. The measures include adjustments in import screening, flexibility to manufacturers, and creation of special mailbox service, among other provisions.
  • The emergence of local PPE manufacturers, increasing end user demand, and the rising production of cost-effective and integrated PPE is expected to boost the market growth. For instance, in India, the Union Textiles Ministry and the Health Ministry has said the government is augmenting the supplies of personal protective equipment (PPEs), including body coveralls, N-95 masks and 2-ply/3-ply surgical masks required for healthcare professionals dealing with COVID-19 cases. Furthermore, more than 130 Australian companies have responded to an urgent call to dramatically boost the manufacturing of face masks, gowns, and gloves to deal with the COVID-19 crisis.
Market Restraints
  • The current global stockpile of PPE is inadequate to handle the existing and expected cases in different parts of the world, particularly for medical masks and respirators. The supply of gowns and goggles is also expected to be insufficient as the disease is spread. Surging global demand is not only driven by the increasing number of COVID-19 cases but also by misinformation, hoarding, and panic buying. The lockdown in a significant portion of the world is hampering the manufacturing of PPE.
  • The high cost of raw materials (specialized clothing and other related products) is hindering the demand for PPEs in economically weak countries.

Healthcare Personal Protection Equipment Market Segmentation

By Product
  • Protective Clothing: The protective clothing is further segmented into coveralls, gowns, and others. Coverall/gowns are designed to protect the torso of healthcare providers from exposure to the virus.
  • Respiratory Protection: Respiratory protection is bifurcated into surgical masks, respirator masks, and others. The healthcare professionals are recommended to use surgical N95 respirators or medical respirators to protect them from the direct exposure to the COVID-19 virus.
  • Head, Eye, and Face Protection: The largest segment. To prevent exposure of the eye and face from the virus, goggles or a face shield should be considered. High risk of COVID-19 and other infections through nose, eyes, and ears is among the primary reason driving the growth for this segment. The goggles must fit the contours of the user’s face and are compatible with the respirator. The use of face shields/ goggles is an integral part of standard and contact precautions for the people most at risk of COVID-19 infection.
  • Protective Footwear: The use of protective footwear such as washable and disposable footwear is essential to avoid self-contamination.
  • Hand protection: Hand protection is further sub-segmented into general-purpose, chemical handling, sterile gloves, and surgical. The rising awareness about hygiene and prevention from the transmission of pathogens in healthcare facilities is increasing the demand for medical gloves.
  • Others
By End Use
  • Hospitals & Clinics: The largest segment and expected to grow at the highest CAGR during the forecast period. The rising awareness regarding the hand protection during a viral outbreak is increasing the demand for PPEs in hospitals.
  • Ambulatory Surgical Centers: The increasing number of patients visiting surgical centers is facilitating the demand for PPEs in ambulatory surgical centers.
  • Academic and Research Institutes: PPEs are very effective in minimizing occupational injuries, accidents, and other hazards which otherwise result in substantial manpower and financial losses. The use of basic PPE is a must in research institutes as they protect from skin contact and contamination.
  • Diagnostic Laboratories: The use of protective equipment is necessary for diagnostic laboratories to protect healthcare workers from specific hazards and hazardous materials.
  • Others
By Region
  • Americas: The largest regional market. The increasing government initiatives and rising concerns in terms of health and safety of healthcare professionals is boosting the demand for the same. Moreover, the rising prevalence of COVID-19 infection is majorly contributing to the growth of this region.
  • Europe: The healthcare market in Northern European economies, such as Germany, U.K., and Sweden, is expected to exhibit an increase in healthcare expenditure, thereby leading to the growth in production as well as the consumption of medical devices and products.
  • Asia-Pacific: The fastest-growing regional market. Emerging market players in the region, technological advancements, rising focus of government towards healthcare facilities, and high target population in the region are among the key factors driving the market growth in the region.   
  • Middle East & Africa: The high penetration of personal protective equipment in developed healthcare industries of UAE, South Africa is expected to drive the growth of the market in this region.
Posted by at No comments:

Worldwide Particle Counter Market Booming Industry Size And Revenue | Future Vision Footbridge 2025 In Healthcare Sector

Market Forecast
Global Particle Counter Market size is expected to cross USD 168.2 Million by 2025 at a CAGR of 7.1% during the forecast period of 2019 to 2025.
Market Synopsis
A particle counter is a tool for monitoring indoor air quality to understand the concentration of particles in the air in cleanrooms and workplaces. This device would not identify specifically what kinds of dust particulates are present in the air, but it will identify how many airborne particles of a certain size are present in the environment.
The growing pharmaceutical sector along with stringent regulatory policies are driving the particle counter market growth. Additionally, increasing numbers of growth strategies adopted by major players are further driving the market growth globally. For instance, in June 2019, TSI launched the AeroTrak+ Remote Airborne Particle Counters for monitoring manufacturing cleanrooms.
Market Influencer
Rising production by the pharmaceutical industry and stringent regulations are likely to impact the growth of the particle counter industry positively.
Market Drivers
  • The growing pharmaceutical industry will support the growth of the particle counter market during the forecast period.
  • Rising research & development in the pharmaceutical and biotechnology industry to cater to rising needs for treatments of various chronic diseases is driving the growth of the particle counter market. For instance, according to a recent survey, the pharmaceutical and biotechnology industry in the US spent a total of USD 102 billion on research & development in 2015. Additionally, according to the National Institute for Health Research, the Association of the British Pharmaceutical Industry (ABPI) invested over USD 4.46 billion just in the UK on R&D, looking for breakthroughs for conditions such as cancer, dementia, and rare genetic diseases.
  • Stringent government regulations regarding the quality of air in the pharmaceutical and medical device industry.
  • Rising product launches and product advancements by major market players.
Market Restraints
  • The high cost of particle counters and technical limitations of particle counters is hampering the growth of the global particle counter market.
Particle Counter Market Segmentation
By Product Type
  • Airborne Particle Counters: Airborne particle counters are widely used to monitor signs of cleanroom air contamination, and, in most cases, the particle count data is used to make critical process decisions regarding cleanroom certifications. These airborne particle counters, work on a light scattering principle. They utilize a very bright light source to illuminate the particles.
  • Liquid Particle Counters: Liquid particle counting is used to measure the size and distribution of particles in a liquid or on solid samples. This particle counter works by irradiating a liquid sample with a laser diode and detecting the scattered light. The properties of the scattered light are related to the particle size. The particle size is then measured, and the number of particles present in each size range is determined. Aviation & space exploration, heavy machinery, and automobile manufacturing are the fields where particle control in hydraulic systems plays an important role.
By Technology
  • Online Particle Counters: Online/Inline measuring systems are designed to mount directly to stationary systems for continuous or periodic monitoring or can be used as mobile monitoring solutions in hydraulic and lubricating systems.
  • Offline Particle Counters: Offline particle counters use mineral as the operating fluid, and their portable size makes them most suitable for on-site applications. These particle counters are widely used for automatically measuring & displaying particulate contamination, moisture & temperature levels in various hydraulic fluids.
By Modularity
  • Portable Particle Counters: The portable particle counter holds the majority share in the modularity segment attributing to the high adoption rate of these systems across the globe. Portable particle counters are easy to handle and are designed to save time and money. Demand for portable particle counters is rapidly growing in aerospace, automotive, pharmaceutical, oil & gas, and food & beverage industries.
  • Remote Particle Counters: Remote Particle counters are perfect for monitoring large cleanrooms or critical environments. Their small size, flexible power options, and wireless capabilities make them a preferred option for large clean rooms.
  • Handheld Particle Counters: These particle counters being lightweight and easy to carry, well-suited for cost-effective spot-checking. They are ideal for checking sources of contamination and perform indoor air quality (IAQ) investigations for consistently meeting the air quality parameters.
By End-User
  • Medical Device Industry: In 2018, the medical device industry held the largest share in the market due to increased R&D expenditure and the establishment of new manufacturing facilities by global pharmaceutical giants in newer geographies. Additionally, increasing infections arising due to contaminated devices and the implementation of stringent regulations to maintain air quality is driving the market growth.
  • Pharmaceutical Industry: Pharmaceutical industry accounted for the second-largest market share due to the growing volume of compounds to be detected for the presence of impurities in pharmaceutical samples and stringent safety regulations. Effective sterilization processes are vital within the pharmaceutical industries, and the safety of process units and final products depends on the highest quality of hygienic practice, as well as strict controls and regulatory compliance. Air quality rules and regulations need to be complied to ensure that the product remains sterile. This leads to a rise in the particle counter market as pharmaceutical firms are emphasizing on the use of particle counter methods to ensure air quality.
  • Research Laboratories: Particle countering is a key factor of air quality monitoring in laboratories where products or processes are sensitive to environmental contamination.
  • Others: Others include hospitals, specialty centers, diagnostic centers.
By Region
  • Americas: The Americas held the largest regional market share in 2018. This is owing to the high adoption rate of particle counters and stringent regulations by the FDA. Additionally, product launches and product advancements by major market players are driving the growth in the Americas region.
For instance, in February 2018, Particle Plus launched Particles Plus 2000 series in four size channels—0.3, 0.5, 1.0, and 5.0 µm.
  • Europe: The need for particle counter is high in this region due to growth in the pharmaceutical and medical device industry. Additionally, increasing support from governments, the presence of a huge geriatric population, and rising healthcare spending are driving the market growth.
  • Asia-Pacific: The Asia-Pacific region accounted for the third-largest market share due to presence of a large number of research organizations, low manufacturing cost and labor cost, developing healthcare infrastructure, and increased investments by the American and European market giants in Asian countries such as China and India
  • Middle East & Africa: It is estimated to account for the least share of the global particle counter market due to the limited development of healthcare facilities.
Posted by at No comments:

Whole Exome Sequencing Market Key Manufactures Shares, Analysis And Forecasts Till 2025

Market Overview
Global Whole Exome Sequencing Market size is expected to register a CAGR of 19.80% to reach USD 2,696.03 Million by 2025.
Synopsis
Whole exome sequencing is a widely used next-generation sequencing (NGS) method to determine the nucleotide sequence primarily of the protein-coding regions of an individuals related sequences, representing approximately 1% of the complete DNA sequence. The human exome represents less than 2% of the genome but contains ~85% of known disease-related variants. This is the key reason for the usage of exome in the identification and the determination of genetic variants causing various diseases such as Miller syndrome and Alzheimer’s.
Factors that drive the market growth are the decreasing cost of sequencing, the use of whole-exome sequencing technology for varied applications, and strategic alliances amongst key players & research institutes. However, the lack of skilled professionals and ethical & legal issues related to whole-exome sequencing are hampering the growth of the market.
Market Dynamics
Market players operating in the global whole exome sequencing market are focusing on product launches, approvals, and partnerships to gain market dominance and keep their product updated and in demand. For instance, in November 2019, NantHealth, Inc. (US), a next-generation, personalized healthcare company, received FDA authorization of Omics CoreSM, the first whole-exome sequencer used to analyze both tumor and somatic gene to measure overall tumor mutational burden (TMB) in cancer tissue.
Segmentation
Global Whole Exome Sequencing Market has been segmented on the basis of Product, Technology, Application, and End User. The market, based on product, has been segmented into kits, sequencer, and services. Kits are further segmented into DNA Fragmentation, End Repair, A-Tailing, And Size Selection Kits, Library Preparation, and Target Enrichment. Services are further sub-segmented into Sequencing Services, Data Analysis (Bioinformatics), and Others. The global whole exome sequencing market, by technology, has been categorized as Sequencing by Synthesis (SBS), ION Semiconductor Sequencing, and others. The market by application is segmented into diagnostics, drug discovery, and development, agriculture and animal research, others. Based on end user, the market is segmented into research centers and government institutes, hospitals and diagnostics centers, pharmaceutical & biotechnology companies, and others.

Regional Analysis
The Americas was the largest market for whole exome sequencing in 2019. The growth of the Americas market is due to the high prevalence rate of cancer and other chronic disorders and rising healthcare expenditure. Additionally, favorable initiatives by the government and other organizations for the development and adoption of whole-exome sequencing technologies are driving the market for whole-exome sequencing. For instance, in 2018, All of Us Research Program, a part of the National Institutes of Health, awarded funds over USD 28.6 million to establish three genome centers in the US. These centers aim to produce genome data for researchers and the program’s precision medicine research platform, a national resource to support studies on a variety of important health questions.
Europe is the second-largest market for whole exome sequencing with Western Europe, holding the largest market share. The European market is expected to register a sturdy growth rate during the forecast period due to rising cases of cancer and increasing programs for the adoption of genome sequencing. According to the International Agency for Research on Cancer, in 2018, there were about 4,229,662 cases of cancer in Europe. This huge cases of cancer and rising genome mapping programs are expected to have a positive impact on the growth of the whole-exome sequencing market.
Asia-Pacific is expected to represent the highest market growth potential over the forecast period due to the growing patient pool and increasing technological advancements. The fast growth of the Asia-Pacific region is due to the increasing per capita income along with government initiatives to enhance the quality of healthcare. China, India, and Australia have a lucrative market for Whole Exome Sequencing due to the growing older population. Moreover, according to the report published by the United Nations in 2015, the number of older people aged 60 years or above in the world is predicted to grow by 56% between 2015 and 2030. 66% of the older population out of the total global population would also reside in the Asia-Pacific region.
In the Middle East & Africa, the whole exome sequencing market accounts for significant market share. Countries such as Kuwait, the UAE, and Saudi Arabia are likely to show steady growth due to increasing cancer cases, rising initiatives by governments to improve patient care, and favorable reimbursement policies. However, the rest of the Middle East and Africa might show an inactive growth due to affordability and accessibility issues.
Key Players
The Prominent Players in the Global Whole Exome Sequencing Market are Illumina Inc. (US), BGI (China), Eurofins Scientific (Belgium), Thermo Fisher Scientific (US), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), GENEWIZ (US), Ambry Genetics (US), Macrogen, Inc. (South Korea), Integragen SA (France), and others.
Posted by at No comments:

Immunofluorescence Assay Market 2023 Forecasts By Global Industry Analysis In 2019 Report

Market Scenario
The growing prevalence of chronic and infectious diseases increase in research and development activities, growing government investments for R&D activities, increased need for rapid and sensitive diagnostics, and adoption of technologically advanced systems are the key factors for the market to grow. However, factors such as, expensive diagnostic kits, chances of cross contaminations, shortage of skilled labor and weak detection signals are expected to restrict the market growth during the forecast period.
The Global Immunofluorescence Assays Market size is expected to reach an approximate CAGR of 5.8% during the forecast period.
According to National Institutes of Health (2012), autoimmune diseases are most prevalent among other diseases, and 23.5 million people in America suffer from autoimmune diseases, whereas 9 million people have cancer. Furthermore, according to Alzheimer's Association in 2018, 5.7 million Americans are affected by Alzheimer’s disease.  Thus, such high incidence of autoimmune and neurological diseases and increasing government funding enhances the growth in this market. Also, growing demand for rapid and precise measurement of biomolecules, increased use of Immunofluorescence Assay for diagnostic and research purposes, increased R&D activities and advanced technology are the key factors for the market to grow.
However, factors such as expensive diagnostic kits, chances of cross contaminations, shortage of skilled labor and weak detection signals are expected to restrict the market growth during the forecast period.
Key Players
Some of the key players for the global Immunofluorescence Assay market are Abcam plc, Thermo Fisher Scientific, BioLegend, Inc., Enzo Life Sciences, Inc., Sino Biological Inc.,BioTek Instruments,Inc., Bio-Rad Laboratories, Inc., Zyagen, Cell Signaling Technology, Inc., PerkinElmer Inc. Becton Dickinson and Company , Merck , Agilent Technologies , TCS Biosciences Ltd, Maxvision Biosciences Inc. and Others.
Segmentation
The global immunofluorescence assay market is segmented on the basis of technique, product type, application and end user. The immunofluorescence assay market, by technique is sub segmented into primary (direct) immunofluorescence assays, secondary (indirect) immunofluorescence assays, and micro immunofluorescence. Secondary (indirect) immunofluorescence assays category includes salt split technique, antigenic mapping method and double staining method. On the basis of product type, the market is categorized into antibodies, kits and reagents, instruments, labelling dyes and species type. Instruments is further sub segmented into microscopes and imaging analysis systems. The application segment includes clinical research, clinical diagnostics, research & development. Clinical diagnostics segment is categorized into infectious diseases, cancer, cardiovascular diseases, autoimmune diseases, neurological diseases. On the basis of end-user, the market is segmented into biotechnology companies, hospitals & research institutes, contract research organizations and diagnostic centers.
Regional Market Summary
The Immunofluorescence Assay market is dominated by North America owing to the high prevalence of chronic diseases and high R&D investments within this region stimulate market growth. According to the U.S. Investments in Medical and Health Research and Development in 2016, the United States invested total $171.8 billion in medical and health R&D and the investment increased by 20.6% from 2013 to 2016. Also, the rising adoption of technologically advanced systems for early diagnosis of diseases drives the market growth in this region.
It is estimated that Europe stood second in the global Immunofluorescence Assay market. Rising prevalence of chronic diseases such as cancer is driving the growth of this market in Europe. According to the Eurostat in 2014, 272 thousand people deaths were due to lung cancer. Thus, increasing prevalence of cancer in Europe drives the market growth. Furthermore, rapidly growing biotechnology sector in Europe is expected to boost the market in this region.
Asia Pacific was projected to be the fastest growing region for the global Immunofluorescence Assay market. Key factors such as growing patient pool, high incidence of chronic diseases, developing healthcare infrastructure and increasing research & development activities in biotechnology sector influences the market in this region. Also, the presence of major market players China, India, and Japan drive the market growth.
The Middle East and Africa holds the least share in the global Immunofluorescence Assay market due to the presence of stringent government policies and poor economies. However, growing awareness among the population and high investments by private market players in this region can boost the market growth. 
Posted by at No comments:

Worldwide Glioma Diagnosis and Treatment Market Booming Industry Size And Revenue | Future Vision Footbridge 2023 In Healthcare Sector

Market Scenario
A Glioma is a type of tumor that originates in the brain and is also known as a primary brain tumor. There are numerous types of gliomas which are entitled based on the origin of the cell type including oligodendrogliomas, astrocytoma, ependymomas, and glioblastoma. Nearly 33 percent of all brain tumors are gliomas. These originate in glial cells surrounding the neurons in the brain.
Global Glioma Diagnosis and Treatment market is expected to grow at a CAGR of approximately 10.1% during the forecast period, 2017–2023.
According to the American Brain Tumor Association, more than 79,000 new cases of primary brain tumors were diagnosed in 2017 with 24.7% of those being gliomas.
Brain tumors are one of the prominent causes of cancer among children and teenagers. Glioma is the most common type of brain tumor which accounts for approximately half of all the astrocytoma. The increasing occurrence of glioblastoma over the years is responsible for the growth of the glioma diagnosis and treatment market. The upcoming drug launches and developments in research are instrumental for the growth of the market. In addition, the current unmet need is expected to drive the gliomas industry over the forecast period. Changing financial demands and access to healthcare facilities are some of the factors that are constraining the market growth.
Astrocytoma is the most common types of glioma diagnosed worldwide, as more than 30% of all the diagnosed cases with brain tumors are astrocytoma. These types of tumors are not curable as they spread easily through normal brain tissue. The American Brain Tumor Association has evaluated that around 7% of all the primary brain tumors represent astrocytoma.
The expanding market for the treatment of brain cancer-associated symptoms, the increasing prevalence of brain cancer, and innovations in drug delivery to brain cancer cells are some of the key factors augmenting the demand in the global glioma diagnosis and treatment market. Furthermore, the introduction of novel therapies coupled with various organizations generating awareness and increasing geriatric population are factors driving the growth of the global glioma diagnosis and treatment market.
Key Players
Some of the key players in the global glioma diagnosis and treatment market are Thermo Fisher Scientific Inc. (U.S.), Emcure Pharmaceuticals Ltd. (India), Sigma-Aldrich Co. (U.S.), Pfizer Inc. (U.S.), Taj Pharmaceuticals Limited (India), Novartis International AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), GE Healthcare (U.S.), Siemens Healthineers (U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan), Merck & Co., Inc. (U.S.), F. Hoffmann-Le Roche AG (Switerland), Arbor Pharmaceuticals, LLC (U.S.), Sun Pharmaceutical Industries, Ltd. (India), Amneal Pharmaceuticals. LLC (U.S.), AstraZeneca (UK), Carestream Health (U.S.), Hitachi Medical Corporation (U.S.), and others.
Segmentation
Geographically, the Americas glioma diagnosis and treatment market is segmented into two major regions, namely, North America and South America.
North America accounted for the largest share of the global gliomas industry in 2016, and the trend is expected to continue over the projected period. Moreover, it is anticipated that about 80,000 new cases will be registered related to brain tumors in the year 2017 which includes 26,000 primary malignant brain tumors.
The Americas glioma diagnosis and treatment market is segmented on the basis of type, diagnosis, treatment, grade, location, and end-user.
Regional Analysis
The global glioma diagnosis and treatment market consist of four major regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
Growing medical tourism and prevalence of metastatic tumors that require surgical procedures are favoring the growth of the market in the Middle East and Africa. In addition, the development of drug delivery technologies, a combination of modern diagnostic techniques, and increasing awareness of various types of brain tumors are similarly supporting the growth of this market.
The Americas dominates the market owing to the key players domiciled in these regions coupled with the increasing incidences of brain tumor, rising awareness among people, and increasing healthcare expenditure. Brain tumor is the third most common types of cancer in adults in North America. According to the North American Brain Tumor Coalition over 44,500 people in the U.S. were diagnosed with a primary tumor in the brain in 2014. Thus, the increasing incidences of primary brain tumor support the growth of the malignant glioma treatment in North America.  
Asia Pacific is estimated to be the most lucrative market for gliomas due to the increasing occurrence of brain tumors in Asia Pacific countries such as China and others. The growth in the Asian market is fueled by the expanding healthcare infrastructure and presence of untapped market opportunities in this region. This region is considered as an emerging market owing to the increasing number of manufacturers coupled with the increasing market penetration.
Posted by at No comments:
Subscribe to: Posts (Atom)